HomeCompareDRCR vs ABBV

DRCR vs ABBV: Dividend Comparison 2026

DRCR yields 15810.28% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DRCR wins by $5099625632144626688.00M in total portfolio value
10 years
DRCR
DRCR
● Live price
15810.28%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5099625632144626688.00M
Annual income
$5,036,954,671,857,237,000,000,000.00
Full DRCR calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — DRCR vs ABBV

📍 DRCR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDRCRABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DRCR + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DRCR pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DRCR
Annual income on $10K today (after 15% tax)
$1,343,873.52/yr
After 10yr DRIP, annual income (after tax)
$4,281,411,471,078,651,400,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, DRCR beats the other by $4,281,411,471,078,651,400,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DRCR + ABBV for your $10,000?

DRCR: 50%ABBV: 50%
100% ABBV50/50100% DRCR
Portfolio after 10yr
$2549812816072313344.00M
Annual income
$2,518,477,335,928,618,700,000,000.00/yr
Blended yield
98.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DRCR
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DRCR buys
0
ABBV buys
0
No recent congressional trades found for DRCR or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDRCRABBV
Forward yield15810.28%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$5099625632144626688.00M$102.3K
Annual income after 10y$5,036,954,671,857,237,000,000,000.00$24,771.77
Total dividends collected$5095481171683417088.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DRCR vs ABBV ($10,000, DRIP)

YearDRCR PortfolioDRCR Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,591,728$1,581,027.67$11,550$430.00+$1.58MDRCR
2$236,896,184$235,193,035.79$13,472$627.96+$236.88MDRCR
3$32,967,202,559$32,713,723,641.52$15,906$926.08+$32967.19MDRCR
4$4,289,987,547,972$4,254,712,641,233.64$19,071$1,382.55+$4289987.53MDRCR
5$522,030,754,674,911$517,440,467,998,580.90$23,302$2,095.81+$522030754.65MDRCR
6$59,404,535,492,267,464$58,845,962,584,765,304.00$29,150$3,237.93+$59404535492.24MDRCR
7$6,321,863,293,246,202,000$6,258,300,440,269,476,000.00$37,536$5,121.41+$6321863293246.16MDRCR
8$629,205,300,300,649,600,000$622,440,906,576,876,100,000.00$50,079$8,338.38+$629205300300649.63MDRCR
9$58,570,990,922,793,150,000,000$57,897,741,251,471,470,000,000.00$69,753$14,065.80+$58570990922793152.00MDRCR
10$5,099,625,632,144,627,000,000,000$5,036,954,671,857,237,000,000,000.00$102,337$24,771.77+$5099625632144626688.00MDRCR

DRCR vs ABBV: Complete Analysis 2026

DRCRStock

Dear Cashmere Holding Company designs, manufactures, and sells ready to wear luxury cashmere apparel. It offers female, male, and couple mink and cashmere sweaters; cashmere and mink cashmere yarns; and clothing accessories. The company markets its products primarily in China and Hong Kong. It develops Swifty Global, a mobile centric ecosystem which allows customers to conduct their daily activities from investing and making sports predictions to booking transport, meals, and entertainment through a single application. Dear Cashmere Holding Company was founded in 2007 and is based in Baoding, China.

Full DRCR Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DRCR vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DRCR vs SCHDDRCR vs JEPIDRCR vs ODRCR vs KODRCR vs MAINDRCR vs JNJDRCR vs MRKDRCR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.